Dr. Falk Pharma Gmbh

Markus Pröls

Roland Greinwald

Rudolph Wilhelm

Ralf Mohrbacher

Rudolf Wilhelm

Peter Fickert

Erik Fischer

Tanju Nacak

Heidi Waenerlund Poulsen

Michael Trauner

Ansgar Bögershausen

Ralph Müller

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

Pharmaceutical formulation for the treatment of inflammatory changes to the rectum

The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.

Use of nor-ursodeoxycholic acid for reducing liver fat

The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.

Optimized high-dose mesalazine-containing tablet

The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.

Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size

Growing community of inventors

Freiburg/Breisgau, Germany

Markus Pröls